vyvanse glp 1 Medication for binge eating: How to treat binge eating disorder? Medicare launches first GLP-1 weight-loss

Description

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

Yes, but with a caveat

External resources SURMOUNT-4 Trial: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (JAMA) Body Composition Changes During Weight Reduction With Tirzepatide in SURMOUNT-1 (PMC) For researchers serious about building an effective weight loss protocol, SeekPeptides provides comprehensive guides, evidence-based protocols, and a supportive community that has helped thousands navigate their peptide research journey with confidence and clarity